Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:05am, Thursday, 24'th Oct 2024
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
This Biotech Stock Could Rocket 800%, Analyst Says
09:50am, Thursday, 24'th Oct 2024
EF Hutton analyst Jason Kolbert initiated coverage of shares of cancer-immunotherapy biotech ImmunityBio with a Buy rating and a $30 price target on Wednesday.
3 Absurdly Cheap Stocks That Pay High Dividends
08:15am, Thursday, 24'th Oct 2024
These stocks are trading at less than 15 times their expected future profits.
Merck's KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
06:45am, Thursday, 24'th Oct 2024
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CDC'S ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older.
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
08:43am, Wednesday, 23'rd Oct 2024
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.
Modifi Biosciences Acquired by Merck
07:05am, Wednesday, 23'rd Oct 2024
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat ca
Merck (MRK) Advances While Market Declines: Some Information for Investors
06:56pm, Tuesday, 22'nd Oct 2024
Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.
3 Attractive Biotechs With Recent Positives
04:17pm, Monday, 21'st Oct 2024
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
04:00pm, Monday, 21'st Oct 2024
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.
Gilead, MRK Report Data From Investigational Combination Study for HIV
02:50pm, Monday, 21'st Oct 2024
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from
Merck RSV jab has the potential to protect infants
03:29am, Friday, 18'th Oct 2024
Merck & Co Inc's (NYSE:MRK, ETR:6MK) experimental treatment for respiratory syncytial virus (RSV) has shown positive results in a mid- to late-stage trial, moving the company closer to seeking regulat
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
06:06pm, Thursday, 17'th Oct 2024
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants.
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
06:00pm, Thursday, 17'th Oct 2024
Merck said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial. The pharmaceutical giant could emerge as a new
